Claims
- 1. A regime or regimen for preventively or curatively treating a bacterial colonization infesting/infecting an individual subject, comprising administering to an individual subject in need of such treatment, a thus-effective amount of at least one retinoid compound selected from the group consisting of:
6-[3-(1-Adamantyl)-4-methoxy-5-hydroxyphenyl]-2-naphthoic acid; 4-[4-(6-Methoxymethoxy-4′-methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 4-[4-(6-Methoxy-4′-methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 6-[2-Methyl-4-hydroxy-5-(1-adamantyl)phenyl]-2-naphthoic acid; 4-(3-(3,5-Di-tert-butyl-4-oxocyclohexa-2,5-dienylidene)prop-1-ynyl]benzoic acid; 2-Hydroxy-4-[4-(4′-methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 2-[3-(1-Adamantyl)-4-methoxyphenyl)ethynyl]-4-thiophenecarboxylic acid; 4-[4-(4,4′-Dimethylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 4-Hydroxy-2′(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) [1,1′,4′,1″]terphenyl-4″-carboxylic acid; 2″-Hydroxy-2′-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) (1,1′,4′,1″]terphenyl-4″-carboxylic acid; 6-(3-Adamantan-1-yl-5-bromo-4-hydroxyphenyl)-naphthalene-2-carboxylic acid; 4-[4-(6,4′-Dimethylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 2′-(4,4-Dimethylthiochroman-6-yl) [1,1′,4′,1″]terphenyl-4″-carboxylic acid; 2′-(3-Hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) [1,1′,4′,1″]terphenyl-4″-carboxylic acid; 4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphtho-[2,3-b]thiophen-2-yl)benzoic acid; 4-[(6-Hydroxy-7-(1-adamantyl)-2-naphthyl]benzoic acid; 4-(2-Nonyloxyimino-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)acetylamino]benzoic acid; 4-[3-Adamantan-1-yl-4-(2-methoxyethoxymethoxy)-phenylethynyl)-2-hydroxybenzoic acid; 4-[[3-(1-Adamantyl)-4-[(2-methyl-3-hydroxypropyloxy)phenyl]ethynyl]]benzoic acid; 2-Hydroxymethyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydroanthracen-2-yl)phenol; 4-[4-(4′-Propylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 2-Hydroxy-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-ylselanylethynyl)benzoic acid; 2′-(3-Methoxy-5,5,8,8-tetramethyl-5,6,7, 8-tetrahydronaphthalen-2-yl) [1,1′,4′,1″]terphenyl-4″-carboxylic acid; 6-[Butoxy-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)methyl]naphthalene-2-carboxylic acid; 4-[3-(1,1-Dimethyldecyl)-4-methoxybenzoylamino]benzoic acid; 4-(3-Adamantan-1-yl-4-hexyloxybenzoylamino)benzoic acid; 6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-napthylmethanol; 2-Hydroxy-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydroanthracen-2-yl)benzoic acid; 2-(3-Adamantan-1-yl-4-hydroxyphenyl)benzofuran-5-carboxylic acid; 4-(6-methoxycthoxymethoxy-7-(1-adamantyl)-2-naphthyl]salicylic acid; (E)-4-[4-(5-Methoxymethoxy-4′-methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 4-[4-(3-Methoxy-4′-methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-ylselanylethynyl)benzoic acid; 2-Methoxymethoxy-2′-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) [1,1′,4′,1″]terphenyl-4″-carboxylic acid; 2-Hydroxy-2′-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) [1,1′,4′,1″]terphenyl-4″-carboxylic acid; 4-[(Z)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-undecenamido]benzoic acid; 4-[4-(4′-Methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 2′-Propoxy-5′-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)bipheny1-4-carboxylic acid; 4-[2-Heptyloxyimino-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)acetylamino]benzoic acid; 6-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)naphthalene-2-carboxylic acid aimide; (2-Dimethylaminoethyl)amide of 6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid; 2-Hydroxy-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylselanylethynyl)benzoic acid; 2′-(3-Methoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) [1,1′,4′,1″]terphenyl-4″-carboxylic acid; 3-Hydroxy-2′-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) [1,1′,4′,1″]terphenyl-4″-carboxylic acid; and 3-(5′-Adamantan-1-yl-4′-methoxy-2′-methylbiphenyl-3-yl) acrylic acid.
- 2. The regime or regimen as defined by claim 1, comprising treating a pathological disease state, condition or affliction caused by said bacterial colonization.
- 3. The regime or regimen as defined by claim 1, comprising treating a cutaneous infection induced by said bacterial colonization.
- 4. A method for the cleansing of human skin afflicted with an objectionable bacterial colonization comprising topically applying thereon a thus-effective amount of at least one retinoid compound as defined in claim 1.
- 5. A method for deodorizing or correcting the odor of human skin afflicted with a malodorous bacterial colonization, comprising topically applying thereon a thus-effective amount of at least one retinoid compound as defined in claim 1.
- 6. The regime or regimen or method as defined by any of claims 1, 4 or 5, said bacterium responsible for said bacterial colonization comprising Staphylococcus aureus.
- 7. The regime or regimen or method as defined by any of claims 1, 4 or 5, said bacterium responsible for said bacterial colonization comprising Propionibacterium acnes.
- 8. The regime or regimen as defined by claim 3, said cutaneous infection comprising scalded skin syndrome.
- 9. The regime or regimen as defined by claim 2, said pathological disease state, condition or affliction including impetigo.
- 10. The regime or regimen as defined by claim 2, said pathological disease state, condition or affliction including atopic dermatitis.
- 11. The regime or regimen as defined by claim 10, said at least one retinoid compound being selected from the group consisting of:
4-[4-(6-Methoxymethoxy-4′-methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 4-[4-(6-Methoxy-4′-methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 4-[6-Methoxyethoxymethoxy-7-(1-adamantyl)-2-naphthyl]salicylic acid; (E)-4-[4-(5-Methoxymethoxy-4′-methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 4-[4-(3-Methoxy-4′-methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 2-Methoxymethoxy-2′-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) [1,1′,4′1″]terphenyl-4″-carboxylic acid; 4-[4-(4′-Methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; and 4-[4-(4′-Propylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid.
- 12. The regime or regimen as defined by claim 2, said pathological disease state, condition or affliction including acne.
- 13. The regime or regimen as defined by claim 12, said at least one retinoid compound being selected from the group consisting of:
6-[3-(1-Adamantyl)-4-methoxy-5-hydroxyphenyl]-2-naphthoic acid; 4-[3-(3,5-Di-tert-butyl-4-oxocyclohexa-2,5-dienylidene)prop-1-ynyl]benzoic acid; 2-[3-(1-Adamantyl)-4-methoxyphenyl)ethynyl]-4-thiophenecarboxylic acid; 4-Hydroxy-2′(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) [1,1′,4′1″]terphenyl-4″-carboxylic acid; 2″-Hydroxy-2′-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) [1,1′,4′1″]terphenyl-4″-carboxylic acid; 6-(3-Adamantan-1-yl-5-bromo-4-hydroxyphenyl)-naphthalene-2-carboxylic acid; 2′-(4,4-Dimethylthiochroman-6-yl) [1,1′,4′1″]terphenyl-4″-carboxylic acid; 2′-(3-Hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) [1,1′,4′,1″]terphenyl-4″-carboxylic acid; 4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphtho[2,3-b]thiophen-2-yl)benzoic acid; and 4-[(6-Hydroxy-7-(1-adamantyl)-2-naphthyl]benzoic acid.
- 14. The regime or regimen as defined by claim 1, comprising co-administering to said individual subject a thus-effective amount of at least one other retinoid, D vitamin or derivative thereof, corticosteroid, free-radial scavenger, α-hydroxy or β-keto acid or derivative thereof, ion-channel blocker, or combination thereof.
- 15. The regime or regimen as defined by claim 1, comprising administering to said individual subject a pharmaceutical composition comprising from 0.001% to 10% by weight of said at least one retinoid compound.
- 16. The cosmetic treatment for cleansing, or deodorizing/correcting the odor of human skin as defined by claims 4 or 5, comprising topically applying thereon a physiologically acceptable cosmetic composition comprising from 0.001% to 3% by weight of said at least one retinoid compound.
Priority Claims (1)
Number |
Date |
Country |
Kind |
00/01206 |
Jan 2000 |
FR |
|
CROSS-REFERENCE TO PRIORITY/PCT APPLICATIONS
[0001] This application claims priority under 35 U.S.C. §119 of FR-00/01206, filed Jan. 31, 2000, and is a continuation of PCT/FR01/00280, filed Jan. 30, 2001 and designating the United States (published in the French language on Aug. 9, 2001 as WO 01/56554 A2; the title and abstract were also published in English), both hereby expressly incorporated by reference.
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/FR01/00280 |
Jan 2001 |
US |
Child |
10207777 |
Jul 2002 |
US |